Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;

Casale, Thomas B.; Condemi, John J.; LaForce, Craig; Nayak, Anjuli; Rowe, Michael; Watrous, Marc; McAlary, Margaret; FowlerTaylor, Angel; Racine, Amy; Gupta, Niroo; Fick, Robert B.; Cioppa, Giovanni Della

doi:10.1001/jama.286.23.2956

Cited by 331 publications

(182 citation statements)

References 27 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…The RQLQ has been used in several trials to assess the effect of intranasal glucocorticosteroids (1085,(1089)(1090)(1091)(1092)(1093)(1094), oral H 1 -antihistamines in seasonal (1095)(1096)(1097), perennial (1077,1078) and PER (1066,1067,1098), the combination of intranasal glucocorticosteroids and oral H 1 -antihistamines (1099), leukotriene receptor antagonists (1100, 1101), allergen immunotherapy in pollinosis (1102)(1103)(1104), omalizumab, an anti-IgE monoclonal antibody (768,1105), allergen avoidance (1106) and homeopathy (1107). Studies have also been performed in children (1108).…”

Section: Evolution Of Qol During Interventionsmentioning

confidence: 99%

“…In a large pivotal trial, omalizumab decreased serum-free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis (768,1733). In adults and adolescents, omalizumab was found to decrease all nasal symptoms and to improve RQLQ in patients with rhinitis induced by birch and ragweed pollens as well as in those with sensitization to outdoor allergens (1105,1734).…”

Section: Anti-igementioning

confidence: 99%

“…Anti-IgE monoclonal antibody. The anti-IgE antibody, omalizumab (768,770), has been shown to be effective in patients with allergic rhinitis and moderate/ severe allergic asthma. Its systemic activity and ability to reduce levels of IgE regardless of allergen specificity may be interesting in these respects.…”

Section: Therapeutic Consequencesmentioning

confidence: 99%

See 2 more Smart Citations

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,750

1,755

View full text Add to dashboard Cite

Section: Evolution Of Qol During Interventionsmentioning

confidence: 99%

Section: Anti-igementioning

confidence: 99%

See 1 more Smart Citation

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,750

1,755

View full text Add to dashboard Cite

“…Among these, omalizumab, a humanized monoclonal antibody that binds circulating IgE and prevents its attachment to high-affinity IgE receptors, is the most extensively studied agent approved for the treatment of severe uncontrolled asthma with perennial sensitizations. However, a growing number of reports indicate its effectiveness in seasonal and perennial AR in adults/adolescents [90][91][92][93][94] and children [95][96][97][98][99]. Targeting the early phase of the allergic cascade could prove a significant allergic march-preventing treatment.…”

Section: Other Interventionsmentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

“…The use of omalizumab has been evaluated in several allergic conditions, including allergic rhinitis, asthma, Churg-Strauss syndrome, atopic eczema, urticaria, angioedema, latex allergy, and concurrently with allergy immunotherapy to try to blunt reactions [1][2][3][4][5][6][7][8][9][10]. While approved by US Food and Drug Administration for asthma, the other indications need to be studied further.…”

Section: Introductionmentioning

confidence: 99%

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Yalçın¹

2012

J Aller Ther

View full text Add to dashboard Cite

Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persistent and allergic asthma. Our aim was to evaluate the therapeutic efficacy of omalizumab as a treatment modality in patients with different allergic conditions. Methods: There were eleven patients, whom followed-up with omalizumab therapy in the Immunology -Allergy Clinic, were evaluated by the clinical findings of nasal polyposis, anaphylaxis history, drug allergy, latex allergy, food allergy, autoimmune urticaria, allergic rhino-conjunctivitis, atopic dermatitis, angioedema and venom allergy. Results:The patients, who had severe persistent asthma for periods ranging from 3 to 8 years, were enrolled in the study. Omalizumab was chosen as a potential new systemic therapy for the patients due to the clinical indication. Clinical symptoms of the all patients with severe persistent asthma were decreased. And in addition, asthma control test and pulmonary function tests were improved up. A severe anaphylactic reaction is prevented in a patient with 48 bee stings. Conclusion:This clinical follow-up of omalizumab treated patients with severe persistent asthma and many different allergic conditions, suggests omalizumab is an effective therapy for asthma and different allergic conditions.

show abstract

Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Abstract: Omalizumab decreased serum free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis.

Cited by 331 publications

References 27 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Contact Info

Product

Resources

About